[Metabolic curietherapy with P-32 in bone metastases in breast cancer].
The administration of radioactive phosphorus (P-32) for the treatment of pain in metastatic bone lesions from breast cancer shows palliative effects lasting three to nine months. The evolution of the disease is not modified.
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D001943:Breast Neoplasms; D005260:Female; D006801:Humans; D008875:Middle Aged; D010146:Pain / Q000532:radiotherapy; D010166:Palliative Care; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*; D013739:Testosterone / Q000627:therapeutic use; D013997:Time Factors
D010761:Phosphorus Radioisotopes; D013739:Testosterone
Curieterapia metabólica con P-32 en las metástasis óseas del cáncer de mama.